ZYKADIA

Product Overview

About ZYKADIA

ZYKADIA is a prescription medicine used to treat non-small cell lung cancer (NSCLC) with a specific type of abnormal ALK gene. It is a kinase inhibitor that works by blocking the activity of the abnormal ALK protein, which is involved in the growth and spread of cancer cells.

Key Benefits & Uses

• Treatment of non-small cell lung cancer (NSCLC) with ALK gene mutations
• First-line treatment for ALK-positive NSCLC
• Continuation treatment for ALK-positive NSCLC after initial treatment with chemotherapy

Active Ingredient & Action

ZYKADIA contains the active ingredient ceritinib, which is a potent and selective inhibitor of the ALK tyrosine kinase. By blocking the activity of the abnormal ALK protein, ceritinib helps to slow or stop the growth and spread of cancer cells.

Important Notes

ZYKADIA is available in capsule form for oral administration. It is essential to take ZYKADIA exactly as prescribed by your doctor, and not to stop taking it without consulting your doctor first. Common side effects of ZYKADIA may include nausea, diarrhea, vomiting, and fatigue. If you experience any severe side effects or have concerns about taking ZYKADIA, consult your doctor or pharmacist for advice.